Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Rifaximin Delayed Release 400 mg Tablets in Patients With Moderate-to-severe Papulopustular Rosacea and Positive Lactulose Breath Test. A Multicenter Double-blind, Placebo-controlled Randomized Clinical Trial

NCT03864978 is registered in ClinicalTrials.gov with Alfasigma S.p.A. as lead sponsor.

NCT NCT03864978
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03864978 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Rifaximin Delayed Release 400 mg Tablets in Patients With Moderate-to-severe Papulopustular Rosacea and Positive Lactulose Breath Test. A Multicenter Double-blind, Placebo-controlled Randomized Clinical Trial
Lead sponsor
Alfasigma S.p.A.
Phase
Phase 2
Overall status
Unknown status
Start date
June 22, 2018
Completion date
October 31, 2020
Enrollment
236 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

papulopustular rosacea